Statement: the primary trial recorded the same number of occurences for every type of adverse event.
Primary_evidence: Adverse Events 1:   Total: 3/9 (33.33%)   Fatigue * 1/9 (11.11%)   Non-cardiac chest pain * 1/9 (11.11%)   Sepsis * 1/9 (11.11%)   Urinary tract infection * 1/9 (11.11%)   Syncope * 1/9 (11.11%)   Anxiety * 1/9 (11.11%)   Thromboembolic event * 1/9 (11.11%)